Teva Pharmaceutical Indus에 대한 매도 수량은 투자자에게 Teva Pharmaceutical Indus의 주식 하락에 베팅하는 정도를 알려줍니다. 매도 수량 데이터는 2주마다 업데이트됩니다.

Teva Pharmaceutical Indus (NYSE:TEVA) 주식, 공매도 수량 보고

Teva Pharmaceutical Indus

Teva Pharmaceutical Industries, based in Israel, is the leading generic drug manufacturer in the world. Teva derives half of its sales from North America and makes up a high-single-digit percentage of the total number of generic prescriptions in the US. It also has a significant presence in Europe, Japan, Russia, and Israel. Besides generics, Teva has a portfolio of innovative medicines and biosimilars in three main therapeutic areas: the central nervous system with Copaxone, Ajovy, and Austedo; respiratory with Qvar and ProAir; and oncology with Truxima, Herzuma, and Bendeka/Treanda. Teva also sells active pharmaceutical ingredients, offers contract manufacturing services, and owns Anda, a US-based generic and specialty drug distributor.

Analysts expect Ford Motor Co. (NYSE: F) to post quarterly earnings at 33 cents per share on revenue of $43.25 billion after the closing bell. Ford shares fell 0.7% to $10.09 in after-hours trading.

Equities

News

Markets

Tech

General

ADBE

ADSK

AMZN

AVGO

GOOGL

MSFT

NTRA

NVDA

SBUX

TEVA

TSLA

최근 13F 공시에 따르면 억만장자 투자자 스탠리 드러켄밀러의 가족 투자사인 듀케인(Duquesne)은 브로드컴(NASDAQ:AVGO) 주식을 전량 매각하는 동시에 주요 기술 기업에 대한 투자를 늘렸다.

스탠리 드러켄밀러의 4분기 포트폴리오: 브로드컴 처분, 테슬라·아마존 등 대형 기술주에 대규모 투자

Uber Weride

Mid Cap

Movers

Trading Ideas

AXSM

CRSP

MKGAF

MKKGY

RXRX

SWTX

VNET

이들 10개 대형주는 지난 주 최악의 성과를 거두었다. 그것들이 당신의 포트폴리오에 있나요? 1. 위라이드(NASDAQ:WRD)의 주식이 97.62% 급등했다. 이는 엔비디아(NASDAQ:NVDA)가 13F 제출을 통해 174만 주의 지분을 보유하고 있다고 공개한 후 발생한 일이다.

위라이드, 크리스퍼 및 진DX 등 지난주 최대 상승한 10개의 중형주 (2월 10일-2월 14일)

Record-Breaking Market Losses: Nvidia Tops The List Of The 10 Largest Wipeouts In History

Large Cap

DECK

MANH

SMCI

이들 12개 대형주들은 지난 주 최악의 성과를 거두었다. 그것들이 당신의 포트폴리오에 있나요? 1. 맨해튼 어소시에이츠(NASDAQ:MANH)의 주식은 회사가 2025 회계연도에 대한 부진한 가이던스를 발표한 후 27.92% 급락했다. 애널리스트들이 가격 예측을 하향 조정한 것도 영향을 미쳤다.

엔비디아, 테바 파마 및 UPS 등 지난주 하락한 12개의 대형주 (1월 27일-1월 31일)

Teva Pharmaceutical Industries Limited American Depositary Shares

Teva Pharmaceutical Industries Ltd

TEVA PHARM INDUS LTD ORD by Teva Pharmaceutical Industries Ltd.

TEVANO SYS HLDGS INC by Tevano Systems Holdings Inc.

Tevano Systems Holdings Inc

<a href="https://www.semafor.com/article/04/24/2025/fdas-marty-makary-no-plans-to-pull-abortion-pill-mifepristone" title="https://www.semafor.com/article/04/24/2025/fdas-marty-makary-no-plans-to-pull-abortion-pill-mifepristone">https://www.semafor.com/article/04/24/2025/fdas-marty-makary-no-plans-to-pull-abortion-pill-mifepristone</a>

Biotech

DARE

EVFM

'FDA Commissioner Says 'no Plans' To Pull Abortion Pill Mifepristone' - Financial Times

WIIM

Teva Pharmaceuticals shares are trading higher after the company announced FDA Filing Acceptance for AJOVY.

<ul>
<li>EPYSQLI&#xAE; (eculizumab-aagh) is now available to patients living with difficult-to-treat rare diseases like paroxysmal nocturnal hemoglobinuria, atypical hemolytic uremic syndrome and generalized myasthenia gravis in adults who are anti-acetylcholine receptor antibody positive</li>
<li>EPYSQLI will be available at a 30% discount of the Wholesale Acquisition Cost (WAC) of the reference product, Soliris&#xAE; (eculizumab), making it one of the greatest cost-saving biosimilars to Soliris&#xAE; in the U.S.</li>
<li>Teva and Samsung Bioepis entered into a strategic partnership in January 2025 for the commercialization of EPYSQLI in the U.S., furthering both companies' commitment to bring more accessible treatment options to rare disease patients &nbsp;</li>
</ul>
PARSIPPANY, N.J. and INCHEON, Korea, April 07, 2025 (GLOBE NEWSWIRE) -- Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), and Samsung Bioepis Co., Ltd. today announced the availability of EPYSQLI&#xAE; (eculizumab-aagh) in the U.S. EPYSQLI is a biosimilar to Soliris&#xAE; (eculizumab) for the treatment of paroxysmal nocturnal hemoglobinuria (PNH), atypical hemolytic uremic syndrome (aHUS) and generalized myasthenia gravis (gMG) in adult patients who are anti-acetylcholine receptor (AchR) antibody positive. EPYSQLI will be offered at a 30% discount of the Wholesale Acquisition Cost (WAC) of the reference product, Soliris&#xAE;, offering one of the greatest cost-saving biosimilars to Soliris&#xAE; in the U.S.

Teva And Samsung Bioepis Announce Biosimilar EPYSQLI Injection Now Available In The United States

Teva Announces FDA Filing Acceptance For AJOVY In Pediatric Episodic Migraine Prevention

<ul>
<li>More than 92% of schizophrenia patients taking TEV-'749 in the SOLARIS survey were satisfied or very satisfied with the initiation regimen, dosing schedule and trial medication1</li>
<li>New data from UZEDY&#xAE; (risperidone) evaluated predictors of response in schizophrenia with efficacy observed across patient demographic and clinical characteristics in the Phase 3 RISE trial</li>
<li>Teva continues its commitment to generating clinical insights that help advance and support optimal treatment for individuals living with schizophrenia</li>
</ul>

Teva Highlights Phase 3 SOLARIS Trial Survey Results

Guidance

Teva Pharmaceutical Sees Q1 EPS $0.52 Vs $0.51 Est.; Revenue $3.994B Vs $4.00B Est.

<a href="https://s24.q4cdn.com/720828402/files/doc_financials/2025/q1/Teva-Aide-Memoire-Q1-2025-vF3.pdf">https://s24.q4cdn.com/720828402/files/doc_financials/2025/q1/Teva-Aide-Memoire-Q1-2025-vF3.pdf</a>
&nbsp;
&nbsp;

Teva Pharmaceutical Sees FY25 EPS $2.35-$2.65 Vs $2.58 Est.; Revenue $16.8B-$17.4B Vs $17.10B Est.; Sees First Half Of 2025 Revenues Are Expected To Be Slightly Lower Than Second Half Of 2025 Revenues, With Q1 Revenues Expected To Be Lower Than Q2 Revenues

Financial giants have made a conspicuous bearish move on Teva Pharmaceutical Indus. Our analysis of options history for Teva Pharmaceutical Indus (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TEVA#NYSE">TEVA</a>) revealed 8 unusual trades.
Delving into the details, we found 37% of traders were bullish, while 62% showed bearish tendencies. Out of all the trades we spotted, 6 were puts, with a value of $549,677, and 2 were calls, valued at $54,484.
<h3>Predicted Price Range</h3>
Analyzing the Volume and Open Interest in these contracts, it seems that the big players have been eyeing a price window from $15.0 to $30.0 for Teva Pharmaceutical Indus during the past quarter. 
<h3>Volume &amp; Open Interest Trends</h3>
Looking at the volume and open interest is a powerful move while trading options. This data can help you track the liquidity and interest for Teva Pharmaceutical Indus's options for a given strike price. Below, we can observe the evolution of the volume and open interest of calls and puts, respectively, for all of Teva Pharmaceutical Indus's whale trades within a strike price range from $15.0 to $30.0 in the last 30 days. 
<h3>Teva Pharmaceutical Indus Call and Put Volume: 30-Day Overview</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1743103896_0.png" alt="Options Call Chart" />
<h3>Largest Options Trades Observed:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th align="right">Open Interest</th>
<th align="right">Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>TEVA</td>
<td>PUT</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>03/28/25</td>
<td>$16.05</td>
<td>$14.3</td>
<td>$14.47</td>
<td>$30.00</td>
<td>$144.7K</td>
<td align="right">0</td>
<td align="right">185</td>
</tr>
<tr>
<td>TEVA</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>02/20/26</td>
<td>$6.7</td>
<td>$6.6</td>
<td>$6.7</td>
<td>$22.00</td>
<td>$140.7K</td>
<td align="right">305</td>
<td align="right">211</td>
</tr>
<tr>
<td>TEVA</td>
<td>PUT</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>03/28/25</td>
<td>$14.4</td>
<td>$14.4</td>
<td>$14.4</td>
<td>$30.00</td>
<td>$122.4K</td>
<td align="right">0</td>
<td align="right">85</td>
</tr>
<tr>
<td>TEVA</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>02/20/26</td>
<td>$5.0</td>
<td>$4.95</td>
<td>$5.0</td>
<td>$20.00</td>
<td>$86.5K</td>
<td align="right">326</td>
<td align="right">174</td>
</tr>
<tr>
<td>TEVA</td>
<td>PUT</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>03/28/25</td>
<td>$0.38</td>
<td>$0.32</td>
<td>$0.33</td>
<td>$16.00</td>
<td>$29.7K</td>
<td align="right">713</td>
<td align="right">932</td>
</tr>
</tbody>
</table>

<h3>About Teva Pharmaceutical Indus</h3>
Teva Pharmaceutical Industries, based in Israel, is the leading generic drug manufacturer in the world. Teva derives half of its sales from North America and makes up a high-single-digit percentage of the total number of generic prescriptions in the US. It also has a significant presence in Europe, Japan, Russia, and Israel. Besides generics, Teva has a portfolio of innovative medicines and biosimilars in three main therapeutic areas: the central nervous system with Copaxone, Ajovy, and Austedo; respiratory with Qvar and ProAir; and oncology with Truxima, Herzuma, and Bendeka/Treanda. Teva also sells active pharmaceutical ingredients, offers contract manufacturing services, and owns Anda, a US-based generic and specialty drug distributor.
<h3>Teva Pharmaceutical Indus's Current Market Status</h3>
<ul>
<li>Trading volume stands at 4,251,835, with TEVA's price down by -1.02%, positioned at $15.53.</li>
<li>RSI indicators show the stock to be is currently neutral between overbought and oversold.</li>
<li>Earnings announcement expected in 41 days.</li>
</ul>
<h3>What Analysts Are Saying About Teva Pharmaceutical Indus</h3>
1 market experts have recently issued ratings for this stock, with a consensus target price of $20.0.
Turn $1000 into $1270 in just 20 days?
20-year pro options trader reveals his one-line chart technique that shows when to buy and sell. Copy his trades, which have had averaged a 27% profit every 20 days. <a href="https://www.benzinga.com/premium/ideas/options-moneyline-2/?t=Moop1arja3be22op14&amp;adType=benzinga-insights&amp;ad=options-activity&amp;campaign=wallstreetadvantage">Click here for access</a>. 
&#x2A; An analyst from B of A Securities has decided to maintain their Buy rating on Teva Pharmaceutical Indus, which currently sits at a price target of $20. 
Options are a riskier asset compared to just trading the stock, but they have higher profit potential. Serious options traders manage this risk by educating themselves daily, scaling in and out of trades, following more than one indicator, and following the markets closely.
If you want to stay updated on the latest options trades for Teva Pharmaceutical Indus, <a href="https://www.benzinga.com/pro/">Benzinga Pro</a> gives you real-time options trades alerts.

Options

Teva Pharmaceutical Indus Unusual Options Activity

Deep-pocketed investors have adopted a bullish approach towards Teva Pharmaceutical Indus (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TEVA#NYSE">TEVA</a>), and it's something market players shouldn't ignore. Our tracking of public options records at Benzinga unveiled this significant move today. The identity of these investors remains unknown, but such a substantial move in TEVA usually suggests something big is about to happen.
We gleaned this information from our observations today when Benzinga's options scanner highlighted 9 extraordinary options activities for Teva Pharmaceutical Indus. This level of activity is out of the ordinary.
The general mood among these heavyweight investors is divided, with 44% leaning bullish and 33% bearish. Among these notable options, 5 are puts, totaling $256,004, and 4 are calls, amounting to $166,000.
<h3>Expected Price Movements</h3>
After evaluating the trading volumes and Open Interest, it's evident that the major market movers are focusing on a price band between $13.0 and $25.0 for Teva Pharmaceutical Indus, spanning the last three months.
<h3>Volume &amp; Open Interest Trends</h3>
Looking at the volume and open interest is a powerful move while trading options. This data can help you track the liquidity and interest for Teva Pharmaceutical Indus's options for a given strike price. Below, we can observe the evolution of the volume and open interest of calls and puts, respectively, for all of Teva Pharmaceutical Indus's whale trades within a strike price range from $13.0 to $25.0 in the last 30 days. 
<h3>Teva Pharmaceutical Indus Call and Put Volume: 30-Day Overview</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1742581840_0.png" alt="Options Call Chart" />
<h3>Significant Options Trades Detected:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th>Open Interest</th>
<th>Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>TEVA</td>
<td>PUT</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>03/21/25</td>
<td>$1.14</td>
<td>$0.91</td>
<td>$0.92</td>
<td>$17.00</td>
<td>$114.6K</td>
<td>6.4K</td>
<td>2.8K</td>
</tr>
<tr>
<td>TEVA</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>01/15/27</td>
<td>$5.6</td>
<td>$5.55</td>
<td>$5.55</td>
<td>$13.00</td>
<td>$55.5K</td>
<td>75</td>
<td>200</td>
</tr>
<tr>
<td>TEVA</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>01/15/27</td>
<td>$5.6</td>
<td>$5.35</td>
<td>$5.55</td>
<td>$13.00</td>
<td>$55.5K</td>
<td>75</td>
<td>0</td>
</tr>
<tr>
<td>TEVA</td>
<td>PUT</td>
<td>TRADE</td>
<td>NEUTRAL</td>
<td>03/21/25</td>
<td>$1.21</td>
<td>$0.81</td>
<td>$0.98</td>
<td>$17.00</td>
<td>$49.0K</td>
<td>6.4K</td>
<td>1.3K</td>
</tr>
<tr>
<td>TEVA</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>03/21/25</td>
<td>$1.08</td>
<td>$1.02</td>
<td>$1.05</td>
<td>$17.00</td>
<td>$40.6K</td>
<td>6.4K</td>
<td>862</td>
</tr>
</tbody>
</table>

<h3>About Teva Pharmaceutical Indus</h3>
Teva Pharmaceutical Industries, based in Israel, is the leading generic drug manufacturer in the world. Teva derives half of its sales from North America and makes up a high-single-digit percentage of the total number of generic prescriptions in the US. It also has a significant presence in Europe, Japan, Russia, and Israel. Besides generics, Teva has a portfolio of innovative medicines and biosimilars in three main therapeutic areas: the central nervous system with Copaxone, Ajovy, and Austedo; respiratory with Qvar and ProAir; and oncology with Truxima, Herzuma, and Bendeka/Treanda. Teva also sells active pharmaceutical ingredients, offers contract manufacturing services, and owns Anda, a US-based generic and specialty drug distributor.
In light of the recent options history for Teva Pharmaceutical Indus, it's now appropriate to focus on the company itself. We aim to explore its current performance.
<h3>Present Market Standing of Teva Pharmaceutical Indus</h3>
<ul>
<li>Currently trading with a volume of 4,546,905, the TEVA's price is down by -1.02%, now at $16.07. </li>
<li>RSI readings suggest the stock is currently is currently neutral between overbought and oversold.</li>
<li>Anticipated earnings release is in 47 days.</li>
</ul>
<h3>Expert Opinions on Teva Pharmaceutical Indus</h3>
A total of 1 professional analysts have given their take on this stock in the last 30 days, setting an average price target of $20.0.
Turn $1000 into $1270 in just 20 days?
20-year pro options trader reveals his one-line chart technique that shows when to buy and sell. Copy his trades, which have had averaged a 27% profit every 20 days. <a href="https://www.benzinga.com/premium/ideas/options-moneyline-2/?t=Moop1arja3be22op14&amp;adType=benzinga-insights&amp;ad=options-activity&amp;campaign=wallstreetadvantage">Click here for access</a>. 
&#x2A; An analyst from B of A Securities persists with their Buy rating on Teva Pharmaceutical Indus, maintaining a target price of $20. 
Options are a riskier asset compared to just trading the stock, but they have higher profit potential. Serious options traders manage this risk by educating themselves daily, scaling in and out of trades, following more than one indicator, and following the markets closely.
If you want to stay updated on the latest options trades for Teva Pharmaceutical Indus, <a href="https://www.benzinga.com/pro/">Benzinga Pro</a> gives you real-time options trades alerts.

Teva Pharmaceutical Indus's Options: A Look at What the Big Money is Thinking

Financial giants have made a conspicuous bullish move on Teva Pharmaceutical Indus. Our analysis of options history for Teva Pharmaceutical Indus (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TEVA#NYSE">TEVA</a>) revealed 8 unusual trades.
Delving into the details, we found 62% of traders were bullish, while 37% showed bearish tendencies. Out of all the trades we spotted, 5 were puts, with a value of $155,460, and 3 were calls, valued at $189,620.
<h3>Projected Price Targets</h3>
After evaluating the trading volumes and Open Interest, it's evident that the major market movers are focusing on a price band between $15.0 and $22.0 for Teva Pharmaceutical Indus, spanning the last three months.
<h3>Analyzing Volume &amp; Open Interest</h3>
Looking at the volume and open interest is an insightful way to conduct due diligence on a stock.
This data can help you track the liquidity and interest for Teva Pharmaceutical Indus's options for a given strike price.
Below, we can observe the evolution of the volume and open interest of calls and puts, respectively, for all of Teva Pharmaceutical Indus's whale activity within a strike price range from $15.0 to $22.0 in the last 30 days. 
<h3>Teva Pharmaceutical Indus Call and Put Volume: 30-Day Overview</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1741371339_0.png" alt="Options Call Chart" />
<h3>Largest Options Trades Observed:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th>Open Interest</th>
<th align="right">Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>TEVA</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>01/15/27</td>
<td>$3.95</td>
<td>$3.55</td>
<td>$3.9</td>
<td>$15.00</td>
<td>$77.6K</td>
<td>3.0K</td>
<td align="right">1</td>
</tr>
<tr>
<td>TEVA</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>01/15/27</td>
<td>$3.9</td>
<td>$3.6</td>
<td>$3.88</td>
<td>$15.00</td>
<td>$65.9K</td>
<td>3.0K</td>
<td align="right">201</td>
</tr>
<tr>
<td>TEVA</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>01/15/27</td>
<td>$2.46</td>
<td>$2.06</td>
<td>$2.3</td>
<td>$20.00</td>
<td>$45.9K</td>
<td>3.8K</td>
<td align="right">200</td>
</tr>
<tr>
<td>TEVA</td>
<td>PUT</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>01/16/26</td>
<td>$7.55</td>
<td>$6.9</td>
<td>$6.91</td>
<td>$22.00</td>
<td>$34.5K</td>
<td>1.4K</td>
<td align="right">40</td>
</tr>
<tr>
<td>TEVA</td>
<td>PUT</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>06/20/25</td>
<td>$6.8</td>
<td>$6.75</td>
<td>$6.75</td>
<td>$22.00</td>
<td>$33.7K</td>
<td>9.1K</td>
<td align="right">90</td>
</tr>
</tbody>
</table>

<h3>About Teva Pharmaceutical Indus</h3>
Teva Pharmaceutical Industries, based in Israel, is the leading generic drug manufacturer in the world. Teva derives half of its sales from North America and makes up a high-single-digit percentage of the total number of generic prescriptions in the US. It also has a significant presence in Europe, Japan, Russia, and Israel. Besides generics, Teva has a portfolio of innovative medicines and biosimilars in three main therapeutic areas: the central nervous system with Copaxone, Ajovy, and Austedo; respiratory with Qvar and ProAir; and oncology with Truxima, Herzuma, and Bendeka/Treanda. Teva also sells active pharmaceutical ingredients, offers contract manufacturing services, and owns Anda, a US-based generic and specialty drug distributor.
After a thorough review of the options trading surrounding Teva Pharmaceutical Indus, we move to examine the company in more detail. This includes an assessment of its current market status and performance.
<h3>Present Market Standing of Teva Pharmaceutical Indus</h3>
<ul>
<li>Currently trading with a volume of 4,001,868, the TEVA's price is down by -1.37%, now at $15.14. </li>
<li>RSI readings suggest the stock is currently may be approaching oversold.</li>
<li>Anticipated earnings release is in 61 days.</li>
</ul>
<h3>Professional Analyst Ratings for Teva Pharmaceutical Indus</h3>
Over the past month, 1 industry analysts have shared their insights on this stock, proposing an average target price of $20.0.
Unusual Options Activity Detected: Smart Money on the Move
Benzinga Edge's Unusual Options board spots potential market movers before they happen. See what positions big money is taking on your favorite stocks. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=Be8be9arja3be22bz20&amp;adType=benzinga-insights&amp;ad=options-activity&amp;campaign=wallstreetadvantage">Click here for access</a>. 
&#x2A; An analyst from B of A Securities has decided to maintain their Buy rating on Teva Pharmaceutical Indus, which currently sits at a price target of $20. 
Trading options involves greater risks but also offers the potential for higher profits. Savvy traders mitigate these risks through ongoing education, strategic trade adjustments, utilizing various indicators, and staying attuned to market dynamics. Keep up with the latest options trades for Teva Pharmaceutical Indus with <a href="https://www.benzinga.com/pro/">Benzinga Pro</a> for real-time alerts.

This Is What Whales Are Betting On Teva Pharmaceutical Indus

Teva Pharmaceutical Indus (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TEVA#NYSE">TEVA</a>) has been analyzed by 6 analysts in the last three months, revealing a diverse range of perspectives from bullish to bearish.
In the table below, you'll find a summary of their recent ratings, revealing the shifting sentiments over the past 30 days and comparing them to the previous months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">3</td>
<td align="right">3</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">2</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
In the assessment of 12-month price targets, analysts unveil insights for Teva Pharmaceutical Indus, presenting an average target of $26.83, a high estimate of $30.00, and a low estimate of $20.00. Witnessing a positive shift, the current average has risen by 2.52% from the previous average price target of $26.17.
<img src="https://www.benzinga.com/files/images/story/2025/1741284051_0.png" alt="price target chart" />
<h2>Exploring Analyst Ratings: An In-Depth Overview</h2>
The standing of Teva Pharmaceutical Indus among financial experts is revealed through an in-depth exploration of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Jason Gerberry</td>
<td>B of A Securities</td>
<td>Lowers</td>
<td>Buy</td>
<td>$20.00</td>
<td>$23.00</td>
</tr>
<tr>
<td>Ashwani Verma</td>
<td>UBS</td>
<td>Lowers</td>
<td>Buy</td>
<td>$27.00</td>
<td>$30.00</td>
</tr>
<tr>
<td>Balaji Prasad</td>
<td>Barclays</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$26.00</td>
<td>$28.00</td>
</tr>
<tr>
<td>Ashwani Verma</td>
<td>UBS</td>
<td>Raises</td>
<td>Buy</td>
<td>$30.00</td>
<td>$28.00</td>
</tr>
<tr>
<td>David Amsellem</td>
<td>Piper Sandler</td>
<td>Raises</td>
<td>Overweight</td>
<td>$30.00</td>
<td>$23.00</td>
</tr>
<tr>
<td>Balaji Prasad</td>
<td>Barclays</td>
<td>Raises</td>
<td>Overweight</td>
<td>$28.00</td>
<td>$25.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts frequently update their recommendations based on evolving market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Teva Pharmaceutical Indus. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Offering a comprehensive view, analysts assess stocks qualitatively, spanning from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Teva Pharmaceutical Indus compared to the broader market.</li>
<li>Price Targets: Understanding forecasts, analysts offer estimates for Teva Pharmaceutical Indus's future value. Examining the current and prior targets provides insight into analysts' changing expectations.</li>
</ul>
Understanding these analyst evaluations alongside key financial indicators can offer valuable insights into Teva Pharmaceutical Indus's market standing. Stay informed and make well-considered decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/TEVA/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on Teva Pharmaceutical Indus analyst ratings.</a>
<h2>Delving into Teva Pharmaceutical Indus's Background</h2>
Teva Pharmaceutical Industries, based in Israel, is the leading generic drug manufacturer in the world. Teva derives half of its sales from North America and makes up a high-single-digit percentage of the total number of generic prescriptions in the US. It also has a significant presence in Europe, Japan, Russia, and Israel. Besides generics, Teva has a portfolio of innovative medicines and biosimilars in three main therapeutic areas: the central nervous system with Copaxone, Ajovy, and Austedo; respiratory with Qvar and ProAir; and oncology with Truxima, Herzuma, and Bendeka/Treanda. Teva also sells active pharmaceutical ingredients, offers contract manufacturing services, and owns Anda, a US-based generic and specialty drug distributor.
<h3>Teva Pharmaceutical Indus: Delving into Financials</h3>
Market Capitalization: Indicating a reduced size compared to industry averages, the company's market capitalization poses unique challenges.
Revenue Challenges: Teva Pharmaceutical Indus's revenue growth over 3 months faced difficulties. As of 31 December, 2024, the company experienced a decline of approximately -5.12%. This indicates a decrease in top-line earnings. In comparison to its industry peers, the company trails behind with a growth rate lower than the average among peers in the Health Care sector.
Net Margin: Teva Pharmaceutical Indus's net margin is below industry averages, indicating potential challenges in maintaining strong profitability. With a net margin of -5.13%, the company may face hurdles in effective cost management.
Return on Equity (ROE): Teva Pharmaceutical Indus's ROE lags behind industry averages, suggesting challenges in maximizing returns on equity capital. With an ROE of -3.79%, the company may face hurdles in achieving optimal financial performance.
Return on Assets (ROA): Teva Pharmaceutical Indus's ROA is below industry standards, pointing towards difficulties in efficiently utilizing assets. With an ROA of -0.54%, the company may encounter challenges in delivering satisfactory returns from its assets.
Debt Management: Teva Pharmaceutical Indus's debt-to-equity ratio surpasses industry norms, standing at 3.36. This suggests the company carries a substantial amount of debt, posing potential financial challenges.
<h2>What Are Analyst Ratings?</h2>
Analysts work in banking and financial systems and typically specialize in reporting for stocks or defined sectors. Analysts may attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish "analyst ratings" for stocks. Analysts typically rate each stock once per quarter.
Beyond their standard evaluations, some analysts contribute predictions for metrics like growth estimates, earnings, and revenue, furnishing investors with additional guidance. Users of analyst ratings should be mindful that this specialized advice is shaped by human perspectives and may be subject to variability.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantag">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Analyst Ratings

Forecasting The Future: 6 Analyst Projections For Teva Pharmaceutical Indus

B of A Securities analyst Jason Gerberry maintains Teva Pharmaceutical Indus (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TEVA#NYSE">TEVA</a>) with a Buy and lowers the price target from $23 to $20.

Price Target

B of A Securities Maintains Buy on Teva Pharmaceutical Indus, Lowers Price Target to $20

<a href="https://www.tevausa.com/news-and-media/press-releases/teva-and-medincell-announce-fda-acceptance-of-supplemental-new-drug-application-for-uzedyr-risperidone/" title="https://www.tevausa.com/news-and-media/press-releases/teva-and-medincell-announce-fda-acceptance-of-supplemental-new-drug-application-for-uzedyr-risperidone/">https://www.tevausa.com/news-and-media/press-releases/teva-and-medincell-announce-fda-acceptance-of-supplemental-new-drug-application-for-uzedyr-risperidone/</a>

Teva and Medincell Announces FDA Acceptance Of Supplemental New Drug Application for UZEDY(R) Extended-Release Injectable Suspension As A Treatment For Patients With Bipolar I Disorder

On Saturday, Teva Pharmaceuticals Industries Ltd. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TEVA#NYSE">TEVA</a>) and Sanofi SA (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SNY#NASDAQ">SNY</a>) presented new, detailed results from the RELIEVE UCCD Phase 2b study of duvakitug (TEV&#8217;574/SAR447189) for moderate-to-severe ulcerative colitis (UC) and Crohn&#8217;s disease (CD), the two most common forms of <a target="_blank" href="https://www.benzinga.com/pressreleases/25/02/g43900182/teva-and-sanofi-present-new-positive-phase-2b-study-results-at-ecco-2025-reinforcing-best-in-class" rel="noreferrer noopener">inflammatory bowel disease (IBD)</a>.
These results were shared at the Congress of the European Crohn&#8217;s and Colitis Organisation.
Also Read: <a target="_blank" href="https://www.benzinga.com/general/biotech/25/02/43601535/axsome-therapeutics-resolves-generic-patent-litigation-with-teva-over-depression-drug-analyst-maintains-axsome-as-top-pick-for-2025" rel="noreferrer noopener">Axsome Therapeutics Resolves Generic Patent Litigation With Teva Over Depression Drug, Analyst Maintains Axsome As &#8216;Top Pick For 2025&#8217;</a>
Ulcerative colitis
<ul>
<li>In the UC cohort of the RELIEVE UCCD study, 36% (450 mg dose) and 48% (900 mg dose) of patients treated with duvakitug achieved the primary endpoint of clinical remission (mMS) at week 14 compared to 20% treated with placebo.</li>
<li>Placebo-adjusted rates were 16% (450 mg) and 27% (900 mg) (p=0.050 and 0.003, respectively).
<ul>
<li>Higher clinical remission rates were observed for both doses of duvakitug versus placebo in both advanced therapy (AT)-experienced and AT-naïve subgroups of patients.AT-experienced: 29% (450 mg) and 36% (900 mg), with placebo-adjusted rates of 22% (450 mg) and 29% (900 mg).</li>
<li>AT-naïve: 39% (450 mg) and 53% (900 mg), with placebo-adjusted rates of 12% (450 mg) and 26% (900 mg).1-3</li>
</ul>
</li>
</ul>
Crohn&#8217;s disease
<ul>
<li>In the CD cohort of the RELIEVE UCCD study, 26% (450 mg) and 48% (900 mg) of patients with CD treated with duvakitug achieved the primary endpoint of endoscopic response (SES-CD) compared to 13% on placebo.</li>
<li>Placebo-adjusted rates were 13% (450 mg) and 35% (900 mg) at week 14 (p=0.058 and &lt;0.001, respectively).
<ul>
<li>Higher endoscopic response rates were observed for both doses of duvakitug versus placebo in both AT-experienced and -naïve subgroups of patients.AT-experienced: 11% (450 mg) and 48% (900 mg), with placebo-adjusted rates of 7% (450 mg) and 44% (900 mg).</li>
<li>AT-naïve: 47% (450 mg) and 47% (900 mg), with placebo-adjusted rates of 25% (450 mg) and 25% (900 mg).</li>
</ul>
</li>
</ul>
The company expects to start the Phase 3 program in the second half of 2025.
Price Action: TEVA stock is down 0.18% at $16.70, and SNY stock is down 0.48% at $54.20 during the premarket session on last check Monday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/markets/equities/25/02/43901425/apple-bows-out-of-uks-cloud-encryption-amid-governments-backdoor-demands" target="_blank" rel="noreferrer noopener">Apple Bows Out of UK&#8217;s Cloud Encryption Amid Government&#8217;s &#8216;Backdoor&#8217; Demands</a></li>
</ul>
Photo by Ralf Liebhold via Shutterstock

Health Care

Sanofi/Teva Unveil New Detailed Data For Duvakitug Study Supporting Overall Efficacy For Common Inflammatory Bowel Disease

<ul>
<li>New detailed data from the RELIEVE UCCD study support overall efficacy and safety of duvakitug in all pre-specified subgroups across the different doses</li>
<li>New endpoints presented include findings on clinical and endoscopic outcomes and histological- endoscopic mucosal improvement</li>
<li>Findings to form the basis for a Phase 3 program, anticipated to start in H2 2025</li>
</ul>

Small Business

Reported Saturday, Teva and Sanofi Presented Phase 2b Data At ECCO 2025, Highlighting Duvakitug's Promise For Ulcerative Colitis And Crohn's Disease

ALVO

Teva Pharmaceuticals And Alvotech Announce U.S. Availability of SELARSDI (Ustekinumab-aekn) Injection, A Biosimilar To Stelara For Treatment Of Psoriatic Arthritis, Plaque Psoriasis, Crohn's Disease, Ulcerative Colitis, Pediatric Plaque Psoriasis And Pediatric Psoriatic Arthritis

Teva shares are trading higher after the FDA accepted for review a Biologics License Application for AVT06, a proposed biosimilar to Eylea.

The FDA Has Accepted For Review A Biologics License Application For AVT06, Alvotech's Proposed Biosimilar To Teva Pharmaceuticals' Eylea (Aflibercept), A Biologic Used To Treat Eye Disorders, The Process To Obtain Regulatory Approval Is Anticipated To Be Completed In Q4 2025

Billionaire investor Stanley Druckenmiller&#8216;s family office Duquesne has divested his entire stake in Broadcom, simultaneously increasing his investments in major tech companies, as revealed in a recent 13-F filing.
What Happened: According to a recent&nbsp;SEC filing, Druckenmiller, a seasoned investor, sold all his shares of&nbsp;Broadcom Inc.&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AVGO#NASDAQ">AVGO</a>) in the fourth quarter. This move comes on the heels of his total exit from Nvidia (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVDA#NASDAQ">NVDA</a>), a competing chipmaker, a few months prior.
In the closing months of 2024, Druckenmiller significantly reduced his tech stock portfolio, selling his entire stakes in&nbsp;Microsoft Corp.&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MSFT#NASDAQ">MSFT</a>),&nbsp;Adobe Inc.&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ADBE#NASDAQ">ADBE</a>) and&nbsp;Autodesk Inc.&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ADSK#NASDAQ">ADSK</a>). He also completely sold his stake in&nbsp;Starbucks Corp.&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SBUX#NASDAQ">SBUX</a>) and his shares in insurance company&nbsp;Chubb Ltd.&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CB#NYSE">CB</a>).
Despite these divestments, Druckenmiller increased his investments in several big tech companies in the same quarter, acquiring new positions in&nbsp;Alphabet Inc.&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GOOGL#NASDAQ">GOOGL</a>),&nbsp;Amazon.com Inc.&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMZN#NASDAQ">AMZN</a>), and Elon Musk&#8216;s electric vehicle manufacturer&nbsp;Tesla Inc.&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSLA#NASDAQ">TSLA</a>).
Druckenmiller&#8217;s Duquesne also initiated new investments in United Airlines (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UAL#NYSE">UAL</a>), Delta Air Lines (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DAL#NYSE">DAL</a>), Warner Bros. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WBD#NYSE">WBD</a>), Skechers (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SKX#NYSE">SKX</a>), and Eli Lilly (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LLY#NYSE">LLY</a>).
The most significant holding in his Duquesne Family Office remains Natera (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NTRA#NASDAQ">NTRA</a>), the clinical genetic-testing company in which they held a stake since 2022. Natera holdings account for just over 15% of the portfolio. Meanwhile, the firm increased its stake in Teva Pharmaceuticals (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TEVA#NYSE">TEVA</a>) by nearly 6.3 times. 
SEE ALSO: <a href="https://www.benzinga.com/25/02/43649046/warner-bros-jinjiang-international-collaborate-for-harry-potter-studio-tour-in-shanghai">Warner Bros Announces Shanghai Harry Potter Studio Tour—Set To Be Four Times Larger Than London&#8217;s</a>
Why It Matters: Druckenmiller, who formerly managed hedge funds for George Soros, now manages his own wealth through the Duquesne Family Office, which has investments worth nearly $3.72 billion.
The billionaire investor&#8217;s latest moves follow his earlier divestments in AI stocks. During the third quarter of 2024, <a href="https://www.benzinga.com/markets/equities/24/12/42668157/stanley-druckenmiller-dumps-streets-hottest-ai-stocks-heres-what-the-billionaire-investor-is-betting-on-next">Druckenmiller sold all of its Nvidia shares and significantly reduced its Palantir holdings</a> by 95%. This occurred despite Nvidia and Palantir experiencing significant stock surges that year, with Nvidia&#8217;s stock increasing nearly 190% and Palantir&#8217;s shares gaining over 386%. 
The current quarter&#8217;s exit from Broadcom despite the stock surging more than 100% over the past year appears as a profit booking move. Meanwhile, other additions in big tech stocks show his growing confidence in the sector.
Druckenmiller added Tesla to its portfolio which surged over 83% in the past year. However, the stock plunged more than 16% over the last month, amid declining global sales, regulatory roadblocks in China, earnings disappointment, and Musk&#8217;s increasing political involvement. 
<ul>
<li>READ MORE: <a href="https://www.benzinga.com/25/02/43772576/tesla-to-start-delivering-shanghai-made-refreshed-model-ys-next-week">Tesla&#8217;s Refreshed Model Y Rolls Off Shanghai Gigafactory, Deliveries To Start &#8216;Soon&#8217;</a></li>
</ul>
Image via Shutterstock
Disclaimer:&nbsp;This content was partially produced with the help of AI tools and was reviewed and published by Benzinga editors.

Billionaire Investor Stanley Druckenmiller Dumps Broadcom, Bets Big On Tesla, Amazon And Other Big Tech Stocks In Q4

These ten mid-cap stocks were the best performers in the last week. Are they in your portfolio?
<ol>
<li>WeRide Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WRD#NASDAQ">WRD</a>) shares rocketed 97.62% after NVIDIA Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVDA#NASDAQ">NVDA</a>) disclosed a stake of 1.74 million shares in a 13F filing.</li>
<li>GDS Holdings Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GDS#NASDAQ">GDS</a>) stock escalated 43.45%, probably after President Trump had reportedly postponed tariffs on packages under $800 from China. Additionally, optimism towards China&#8217;s DeepSeek AI model has also lifted stocks recently.</li>
<li>SpringWorks Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SWTX#NASDAQ">SWTX</a>) shares jumped 42.58% after announcing Merck KGaA (OTC:<a class="ticker" href="https://www.benzinga.com/stock/MKGAF#OTC">MKGAF</a>) (OTC:<a class="ticker" href="https://www.benzinga.com/stock/MKKGY#OTC">MKKGY</a>) is in advanced <a href="https://www.benzinga.com//node/43631130" target="_blank" rel="noreferrer noopener">discussions to acquire the company</a>.</li>
<li>Recursion Pharmaceuticals, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RXRX#NASDAQ">RXRX</a>) shares increased 40.59%.</li>
<li>Sable Offshore Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SOC#NYSE">SOC</a>) stock upped 39.09%.</li>
<li>GeneDx Holdings Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WGS#NASDAQ">WGS</a>) shares rose 28.23%  after the company announced UltraRapid Whole Genome Sequencing, which will deliver actionable <a href="https://www.benzinga.com//node/43692155" target="_blank" rel="noreferrer noopener">results within 48 hours</a>.</li>
<li>VNET Group, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VNET#NASDAQ">VNET</a>) stock upped 28.22%, probably amid a possible rebound after falling last week due to AI competition concerns related to China&#8217;s DeepSeek AI model.</li>
<li>Insperity, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NSP#NYSE">NSP</a>) stock increased 25.99% after the company reported better-than-<a href="https://www.benzinga.com//node/43590222" target="_blank" rel="noreferrer noopener">expected fourth-quarter results</a>.</li>
<li>CRISPR Therapeutics AG (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CRSP#NASDAQ">CRSP</a>) stock grew 25.21% after the company reported better-than-<a href="https://www.benzinga.com//node/43639785" target="_blank" rel="noreferrer noopener">expected fourth-quarter financial results</a>. Several analysts raised the price <a href="https://www.benzinga.com/quote/crsp/analyst-ratings" target="_blank" rel="noreferrer noopener">forecast on the stock</a>.</li>
<li>Axsome Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AXSM#NASDAQ">AXSM</a>) stock grew 24.01% after the company reached a settlement agreement with Teva Pharmaceutical (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TEVA#NYSE">TEVA</a>), resolving all patent <a href="https://www.benzinga.com//node/43601535" target="_blank" rel="noreferrer noopener">litigation related to its Auvelity product</a>. Several analysts raised <a href="https://www.benzinga.com/quote/axsm/analyst-ratings" target="_blank" rel="noreferrer noopener">the price forecast on the stock</a>.</li>
</ol>
Photo via WeRide

WeRide, CRISPR And GeneDx Are Among Top 10 Mid-Cap Gainers Last Week (Feb 10-Feb 14): Are The Others In Your Portfolio?

Press Releases

Teva and Alvotech Announce SELARSDI™ (ustekinumab-aekn) Injection Now Available in the U.S.

Teva and Sanofi Present New Positive Phase 2b Study Results at ECCO 2025 Reinforcing Best-in-Class Potential of Duvakitug (Anti-TL1A) in Ulcerative Colitis and Crohn's Disease

Teva and Medincell Announce FDA Acceptance of Supplemental New Drug Application for UZEDY(R) (risperidone) Extended-Release Injectable Suspension as a Treatment for Patients with Bipolar I Disorder

2025 Community Routes: Access to Mental Health Care Grants Awarded to Clinics in Alabama, Mississippi, and Texas, Funded by Teva Pharmaceuticals

Teva to Present at Barclays Global Healthcare Conference and Leerink Partners Global Healthcare Conferences in March

Teva to Host Conference Call to Discuss First Quarter 2025 Financial Results at 8 a.m. ET on May 7, 2025

Earnings

Teva Releases Q1 2025 Aide Memoire

New Data Strengthens Teva's Schizophrenia Portfolio, Including Phase 3 SOLARIS Trial Survey Results Demonstrating Patient and Healthcare Professional Satisfaction with TEV-'749 (olanzapine) as a Once-Monthly Subcutaneous Long-Acting Injectable

Teva Announces FDA Filing Acceptance for AJOVY® (fremanezumab) in Pediatric Episodic Migraine Prevention

Teva and Samsung Bioepis Announce Biosimilar EPYSQLI® (eculizumab-aagh) Injection Now Available in the United States

Amneal Pharmaceuticals, Inc. - Class A Common Stock

Amneal Pharmaceuticals

Axsome Therapeutics

AstraZeneca PLC - American Depositary Shares

AstraZeneca

Bristol-Myers Squibb Company Common Stock

Bristol-Myers Squibb

Corcept Therapeutics Incorporated - Common Stock

Corcept Therapeutics

Elanco Animal Health Incorporated Common Stock

Elanco Animal Health

GSK plc American Depositary Shares (Each representing two Ordinary Shares)

HUTCHMED (China) Limited - American Depositary Shares

HUTCHMED (China)

Haleon plc American Depositary Shares (Each representing two Ordinary Shares)

Haleon

Jazz Pharmaceuticals plc - Ordinary Shares

Jazz Pharmaceuticals

Johnson & Johnson

Eli Lilly

Merck & Co

Novo Nordisk

Novartis

Organon

Prestige Consumer Healthcare Inc. Common Stock

Prestige Consumer

Pfizer

Dr. Reddy's Laboratories Ltd Common Stock

Dr Reddy's Laboratories

Royalty Pharma plc - Class A Ordinary Shares

Royalty Pharma

Sanofi

Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock)

Takeda Pharmaceutical Co

Verona Pharma plc - American Depositary Shares

Comments

Teva Pharmaceutical Indus

매도 수량

Teva Pharmaceutical Indus (NYSE:TEVA) 주식, 공매도 수량 보고

사람들이 또한 지켜본다

뉴스

파트너 / 기고자

벤징가 글로벌